Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.